Anixa Biosciences (NASDAQ:ANIX) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Anixa Biosciences (ANIX) from a "hold" to a "sell"; analyst consensus remains mixed (two Buys, one Hold, one Sell) with an average target price of $8.50.
• Shares opened at $2.55 with a market cap of about $85.5M and a 52-week range of $2.33–$5.46, and the company slightly beat its last quarterly EPS estimate (reported -$0.08 vs. -$0.09 consensus).
• Insider buying: Director Arnold M. Baskies purchased 10,000 shares at $3.04, raising his stake to 135,000 shares; insiders collectively own 26.4% of the company while institutions own about 29.13%.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Anixa Biosciences in a report on Monday, December 29th. D. Boral Capital reissued a "buy" rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Anixa Biosciences presently has an average rating of "Hold" and an average target price of $8.50.

Anixa Biosciences Stock Performance

Shares of ANIX opened at $2.55 on Friday. The company has a market cap of $85.50 million, a price-to-earnings ratio of -7.73 and a beta of 0.57. Anixa Biosciences has a 1-year low of $2.33 and a 1-year high of $5.46. The company's fifty day simple moving average is $2.85 and its 200 day simple moving average is $3.51.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. As a group, research analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Activity

In other Anixa Biosciences news, Director Arnold M. Baskies purchased 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 28th. The shares were acquired at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the purchase, the director owned 135,000 shares of the company's stock, valued at approximately $410,400. The trade was a 8.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 26.40% of the company's stock.

Institutional Trading of Anixa Biosciences

Institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC bought a new position in shares of Anixa Biosciences during the second quarter worth approximately $33,000. Cetera Investment Advisers acquired a new stake in shares of Anixa Biosciences in the fourth quarter valued at approximately $35,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company's stock valued at $35,000 after buying an additional 10,000 shares during the period. Benjamin Edwards Inc. bought a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $37,000. Finally, Millennium Management LLC acquired a new stake in Anixa Biosciences during the fourth quarter worth approximately $38,000. Institutional investors own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.